Current status of epigenetic treatment in myelodysplastic syndromes

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Epigenetic alterations are crucial in cancer development.
• Unlike genetic changes, epigenetic modifications are potentially reversible through pharmacological interventions.
• This reversibility fuels interest in epigenetic therapies for hematologic malignancies.

Purpose of the Study:

• To review the clinical experience with epigenetic drugs, specifically histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors.
• To highlight the role of these agents in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Main Methods:

• Review of existing clinical trial data, primarily focusing on Phase I trials.
• Summary of clinical experience with approved DNMT inhibitors (5-azacytidine, 5-aza-2'-deoxycytidine) in MDS.
• Overview of HDAC inhibitors, including valproic acid, in MDS and AML.

Main Results:

• DNMT inhibitors are FDA-approved for MDS treatment, with ongoing trials for optimized regimens.
• Several HDAC inhibitors have been developed, with valproic acid showing significant clinical experience in MDS and AML.
• Current data for HDAC inhibitors is largely from early-phase clinical trials.

Conclusions:

• Epigenetic therapies, including DNMT and HDAC inhibitors, represent a significant advancement in treating hematologic cancers.
• Further clinical investigation is warranted to optimize the use of these drugs in various dosing schedules and combinations.
• These agents offer a promising avenue for reversing epigenetic dysregulation in MDS and AML.